Inovio announced that the first participant has been dosed with Pennvax-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. This vaccine widely targets all major HIV strains and the potential to enhance the capacity of the immune system to eliminate or provide life-long control of HIV. This trial is part of a previously reported multi-year $6.95M grant from the NIH’s National Institute of Allergy and Infectious Diseases, or NIAID, to develop a single or combination therapy using Inovio’s Pennvax-GP with the goal of attaining long-term HIV remission.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.